In a phase 1b trial of 63 adults with obesity, raised hsCRP and cardiovascular risk, oral ruvonoflast cut hsCRP by 82.2% at Day 28 vs 37.2% with placebo (posterior probability >99%); 4 (10%) on ruvonoflast stopped for adverse events vs none on placebo.
RCTn = 63
Ray et al. Anti-Inflammatory Effects of Oral NLRP3 Inhibition With Ruvonoflast Among Individuals at Elevated Cardiovascular Risk